Yanru Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yanru Qin has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aimin Zang
Hebei Key Laboratory of Cancer Radiotherapy and Chemother-apy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China
1 shared publication - Chenxu Liu
Zhengzhou University First Affiliated Hospital
1 shared publication - Derek Lin
Lung Center, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis School of Medicine (T.V.K., D.A.G., Y.S., L.J., D.L., E.A.G.).
1 shared publication F. Li
Medical Research, Beijing Mabworks Biotech Co. Ltd., Beijing, China
1 shared publication- Hongmei Liu
Academy of National Food and Strategic Reserves Administration, Beijing 100037, China
1 shared publication - Hui-Lian Zhu
Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China
1 shared publication
Latest Publications
- 1 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S778
840P Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- 1 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S778
840P Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- Open Access
- 12 August 2020
- Published by Springer Nature in Research Square
Clinicopathological and Prognostic Characteristics of Hepatoid Adenocarcinoma of the Stomach
Objectives The aim of this study is to analyze the clinical and pathological features of HAS and investigate the factors affecting prognosis.Methods From January 2014 to May 2020, 31 patients were diagnosed as HAS in in the First Affiliated Hospital of Zhengzhou University. The clinicopathologic features and the relevant prognosis of these patients were analyzed.Results Of the 31 patients, 23 were male, with a median age of 62 years. And among the 31 patients, 22 patients underwent a radical gastrectomy and a D2 lymph node dissection. During the follow up period, 18 patients died of the disease. The median OS (mOS) was 28 months. The 1-year survival rate was 55%, the 3-year survival rate was 47%, and the 5-year survival rate was 34%. An elevated CA125 level, distant metastasis, and radical surgery were associated with the prognosis of HAS, and distant metastasis is an independent prognostic risk factor for survival. Conclusion HAS had a poor prognosis because of its frequent vascular involvement, and lymph node and liver metastasis. Aggressive multimodal treatment comprising radical gastrectomy and adjuvant chemotherapy is warranted.This article describes the Clinicopathological of Hepatoid Adenocarcinoma of the Stomach and through survival analysis, the factors affecting the patient’s prognosis were studied.
- 12 August 2020
- Published by Springer Nature in Research Square
Open AccessClinicopathological and Prognostic Characteristics of Hepatoid Adenocarcinoma of the Stomach
Objectives The aim of this study is to analyze the clinical and pathological features of HAS and investigate the factors affecting prognosis.Methods From January 2014 to May 2020, 31 patients were diagnosed as HAS in in the First Affiliated Hospital of Zhengzhou University. The clinicopathologic features and the relevant prognosis of these patients were analyzed.Results Of the 31 patients, 23 were male, with a median age of 62 years. And among the 31 patients, 22 patients underwent a radical gastrectomy and a D2 lymph node dissection. During the follow up period, 18 patients died of the disease. The median OS (mOS) was 28 months. The 1-year survival rate was 55%, the 3-year survival rate was 47%, and the 5-year survival rate was 34%. An elevated CA125 level, distant metastasis, and radical surgery were associated with the prognosis of HAS, and distant metastasis is an independent prognostic risk factor for survival. Conclusion HAS had a poor prognosis because of its frequent vascular involvement, and lymph node and liver metastasis. Aggressive multimodal treatment comprising radical gastrectomy and adjuvant chemotherapy is warranted.This article describes the Clinicopathological of Hepatoid Adenocarcinoma of the Stomach and through survival analysis, the factors affecting the patient’s prognosis were studied.